DLBCL
Novel Agents Expand Rx for Refractory Lymphoma
Boston—Treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) have ...
JUNE 23, 2022
Zynlonta Approved for Relapsed or Refractory Large B-Cell Lymphomas
The FDA granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics) for the treatment ...
MAY 5, 2021
Xpovio Approved to Treat Relapsed or Refractory DLBCL
The FDA granted accelerated approval to selinexor (Xpovio, Karyopharm) for the treatment of adult patients with ...
JUNE 23, 2020
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
Load more